Please use this identifier to cite or link to this item:
http://hdl.handle.net/10609/92581
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Luciano, Juan Vicente | - |
dc.contributor.author | D'Amico, Francesco | - |
dc.contributor.author | Cerdà Lafont, Marta | - |
dc.contributor.author | Peñarrubia-María, M. Teresa | - |
dc.contributor.author | Knapp, Martin | - |
dc.contributor.author | Cuesta Vargas, Antonio Ignacio | - |
dc.contributor.author | Serrano Blanco, Antoni | - |
dc.contributor.author | Garcia-Campayo, Javier | - |
dc.contributor.other | Universidad de Málaga | - |
dc.contributor.other | London School of Economics and Political Science | - |
dc.contributor.other | Universitat Oberta de Catalunya (UOC) | - |
dc.date.accessioned | 2019-03-26T12:11:26Z | - |
dc.date.available | 2019-03-26T12:11:26Z | - |
dc.date.issued | 2014-10-01 | - |
dc.identifier.citation | Luciano Devis, J.V., D'Amico, F., Cerdà-Lafont, M., Peñarrubia-María, M.T., Knapp, M., Cuesta-Vargas, A.I., Serrano Blanco, A. & García-Campayo, J. (2014). Cost-utility of cognitive behavioral therapy versus U.S. food and drug administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Arthritis Research and Therapy, 16(1). doi: 10.1186/s13075-014-0451-y | - |
dc.identifier.issn | 1478-6362MIAR | - |
dc.identifier.uri | http://hdl.handle.net/10609/92581 | - |
dc.description.abstract | Cognitive behavioral therapy (CBT) and U.S. Food and Drug Administration (FDA)-recommended pharmacologic treatments (RPTs; pregabalin, duloxetine, and milnacipran) are effective treatment options for fibromyalgia (FM) syndrome and are currently recommended by clinical guidelines. We compared the cost-utility from the healthcare and societal perspectives of CBT versus RPT (combination of pregabalin + duloxetine) and usual care (TAU) groups in the treatment of FM. | en |
dc.language.iso | eng | - |
dc.publisher | Arthritis Research and Therapy | - |
dc.relation.ispartof | Arthritis Research and Therapy, 2014, 16(1) | - |
dc.relation.uri | https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-014-0451-y | - |
dc.rights | CC BY | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.subject | cognitive behavioral therapy | en |
dc.subject | usual care | en |
dc.subject | fibromyalgia | en |
dc.subject | pregabalin | en |
dc.subject | duloxetine | en |
dc.subject | terapia cognitiva conductual | es |
dc.subject | cuidado usual | es |
dc.subject | fibromialgia | es |
dc.subject | pregabalina | es |
dc.subject | duloxetina | es |
dc.subject | teràpia cognitiva conductual | ca |
dc.subject | atenció habitual | ca |
dc.subject | pregabalina | ca |
dc.subject | duloxetina | ca |
dc.subject.lcsh | Cognition | en |
dc.title | Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.subject.lemac | Cognició | ca |
dc.subject.lcshes | Cognición | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.doi | 10.1186/s13075-014-0451-y | - |
dc.gir.id | AR/xxx | - |
dc.type.version | info:eu-repo/semantics/publishedVersion | - |
Appears in Collections: | Articles Articles cientÍfics |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
costutility.pdf | 763,27 kB | Adobe PDF | View/Open |
Share:
This item is licensed under a Creative Commons License